Effect of chondroitin sulfate on intraocular pressure in rats by Belforte, Nicolás Adalberto et al.
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PURPOSE. To study the effect of intracameral injections of chon-
droitin sulfate (CS) on intraocular pressure (IOP), retinal func-
tion, and histology in rats.
METHODS. Acute or chronic injections of CS were performed
unilaterally in the rat anterior chamber, whereas the con-
tralateral eye was injected with vehicle. IOP was daily or
weekly assessed by a tonometer. Retinal function was as-
sessed by scotopic electroretinography (ERG) and the visual
pathway by flash visual evoked potentials (VEPs), whereas
the retinal and optic nerve head structure were examined by
histologic analysis.
RESULTS. A single injection of 8 mg (but not 2 or 4 mg) CS
induced a significant increase of IOP. The increase of IOP
induced by a single injection of 8 mg CS lasted for 7 days,
whereas chronic (weekly) administration during 10 weeks in-
duced a significant and sustained increase in IOP compared
with eyes injected with vehicle. A significant decrease of
scotopic ERG a- and b- wave amplitude was observed after 6
and 10 weeks of CS administration. Moreover, a significant
decrease in scotopic flash VEP N2-P2 component amplitude
was observed in eyes treated with CS for 6 and 10 weeks. A
significant loss of ganglion cell layer cells and optic nerve
axons was observed in eyes receiving CS for 10 weeks.
CONCLUSIONS. These results suggest that exogenous CS simu-
lates the accumulation of CS in primary open-angle glaucoma
and that increased amounts of CS could play a key role in the
IOP dysregulation characteristic of glaucoma. (Invest Ophthal-
mol Vis Sci. 2010;51:5768–5775) DOI:10.1167/iovs.10-5660
Glaucoma, a leading cause of irreversible visual loss, ischaracterized by loss of retinal ganglion cells (RGCs) and
their axons. Intraocular pressure (IOP) is the most critical risk
factor for primary open-angle glaucoma (POAG). In fact, nearly
all glaucoma therapy relies on lowering the IOP level.1,2 Ele-
vated IOP often results from alterations in aqueous humor
dynamics because of changes in the trabecular meshwork
(TM), leading to impaired drainage of aqueous humor.3 The TM
is a specialized tissue forming a biological filter for aqueous
humor at the chamber angle and is the major site for regulation
of the normal bulk flow of aqueous humor.4 The normal TM
functions as a self-cleaning, unidirectional, pressure-sensitive,
and low-flow (2.75 L/min) filter.5 The TM is divided into the
uveal meshwork, corneoscleral meshwork, and juxtacanalicu-
lar (JCT) regions. In the uveal and corneoscleral meshwork,
sheets of trabecular beams that contain lamellae made of con-
nective tissue or extracellular matrix (ECM) materials are lined
by TM cells. In the JCT region, the cells are embedded in a
loose ECM, and aqueous outflow resistance is believed to
locate largely in the JCT/Schlemm’s canal area.6,7
It is likely that the pressure gradient and the resistance to
aqueous outflow are altered in POAG. The ECM is a major
component of the TM for maintaining aqueous humor outflow.
Glycosaminoglycans (GAGs), key components of TM ECM, are
long linear sugar chains composed of repeating disaccharide
units.8,9 There are five main types of GAGs—chondroitin sul-
fate (CS), dermatan sulfate (DS), heparin/heparan sulfate (HS),
keratan sulfate (KS), and hyaluronic acid (HA)—that vary de-
pending on the identity of their disaccharide units. All GAGs,
except HA, are sulfated in various positions and to various
degrees. For instance, CS chains are commonly sulfated at the
4- and/or 6- hydroxyl positions, DS chains undergo 4- and
2-O-sulfation, whereas HS chains can be N-, 2-O-, 6-O-, and/or
3-O-sulfated.10,11 With the exception of HA, all GAG chains are
covalently attached to and synthesized on core proteins to
form proteoglycans as they move through the endoplasmic
reticulum and Golgi apparatus.12,13 These are then integrated
into the ECM, where they perform many functions, including
cell matrix interactions, growth factor binding, and sequestra-
tion and maintenance of tissue structural integrity.9,13
The GAG concentration of the TM and of the JCT has been
determined by biochemical methods14–18 using sequential en-
zymatic degradation and by histologic staining.19–22 GAGs of
the TM and of the JCT are considered significant contributors
to aqueous outflow resistance in the normal or the POAG TM.
Microscale analysis of single human TMs, using GAG-degrading
enzymes, both biochemical18 and computer-aided microscopy
studies,22 localized and quantitated the various types of GAGs
in the JCT. HA and CS are the predominant types of GAGs in
the normal human TM. In the POAG TM and JCT, HA is
decreased and CS is increased, whereas the total concentration
of GAGs is similar in normal and in POAG TM. Since 1954,
based on the results of the infusion of testicular hyaluronidase
(a GAG enzyme that degrades HA and CS) in bovine eyes, GAGs
were considered to be a factor in aqueous outflow resis-
tance23,24; however, infusion of testicular hyaluronidase in the
human eye does not decrease aqueous outflow resistance.25,26
In the rabbit,27 dog,28 and bovine24 eye, but not in the primate
eye,29 removal of HA correlates with a decrease in aqueous
outflow resistance. Thus, the evidence to date suggests that in
nonprimate species, there is a GAG barrier to aqueous outflow
that is sensitive to testicular hyaluronidase infusion. In primate
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studies, the physiological evidence for the presence of a GAG
barrier to aqueous outflow is inconclusive.29–31 Nonetheless,
Franc¸ois32 believed that excessive amounts of GAGs in POAG
would impede aqueous outflow and increase aqueous outflow
resistance. Certainly, ophthalmic viscosurgical devices (OVDs)
used in ophthalmic surgery may cause a transient and occa-
sionally significant postoperative increase in IOP.33–35 More-
over, the effect of sodium chlorate (a potent inhibitor of GAG
chain sulfation) and -xyloside (which inhibits the elongation
of endogenous GAG chains) was recently assessed in anterior
segment perfusion organ culture and in TM cells in culture.
Both treatments significantly increased outflow facility in hu-
man and porcine eyes, supporting that GAGs play a key role in
outflow resistance in human eyes.36
These observations have led to numerous studies aimed at
determining the functional role of GAGs in POAG. Biochemical
analysis of GAGs from individual POAG TM showed a large
decrease in HA and an increase in CS content in the TM.22
Similar results were reported in a rabbit model37 and a primate
model (DeSantis L, et al. IOVS. 1990;31:ARVO Abstract 99) of
dexamethasone-induced ocular hypertension. These results
suggest that CS could be important in the regulation of aqueous
outflow and that an accumulation of CS in the TM may play a
role in POAG. In fact, it was shown that a larger amount of CS
in POAG juxtacanalicular connective tissue has a greater im-
pact on outflow resistance than the TM concentration of HA.38
In that context, the aim of the present work was to analyze the
effect of increasing CS levels in the rat anterior chamber on




Male Wistar rats (average weight 200  40 g), were housed in a
standard animal room with food and water ad libitum under controlled
conditions of humidity and temperature (21°C  2°C). The room was
lit by fluorescent lights that were turned on and off automatically every
12 hours, with the lights on from 6:00 am to 6:00 pm. All animal
procedures were conducted in strict accordance with the ARVO State-
ment for the Use of Animals in Ophthalmic and Vision Research.
Rats were anesthetized with ketamine hydrochloride (50 mg/kg)
and xylazine hydrochloride (0.5 mg/kg) administered intraperitoneally.
CS was obtained from Sigma Chemical Co. (St. Louis, MO; catalog no.
C9819), isolated from bovine trachea, and composed by 77% CS type
A, 10% CS type B, and 6% proteins, according to the manufacturer.
Using a Hamilton syringe with a 30-gauge needle, 20 L of 0.1, 0.2,
and 0.4 g/mL corresponding to 2, 4, and 8 mg of CS in saline solution
was injected into one eye of each anesthetized rat, and an equal
volume of vehicle (saline solution) was injected in the fellow (control)
eye. The eyes were focused under a surgical microscope (model OMNI
MDU XY; Carl Zeiss, Oberkochen, Germany) with coaxial light. The
needle moved through the corneoscleral limbus to the anterior cham-
ber with the bevel down. When the tip of the bevel reached the
anterior chamber, the liquid progressively increased the chamber’s
depth, separating the needle from the iris and avoiding needle-lens
contact. Applications were made slowly but using a force sufficient to
just empty the syringe content (adjusted to 20 L). In the chronic
protocol, injections were applied at the corneoscleral limbus begin-
ning from hour 12 and changing the site of the next injection from
hour to hour by rotating the head to achieve better access to the
limbus. Injections and IOP assessments were performed after applica-
tion of 1 drop of 0.5% proparacaine hydrochloride to each eye. Rats
showing cataract and animals with phthisis bulbi were excluded from
the experiments. In addition, almost all the animals developed local-
ized corneal edema at the site of the injection that lasted less than 24
hours. No differences in the incidence of these ocular complications
were detected between CS and saline-injected eyes. IOP assessments
were performed at least 24 hours after injections. A tonometer
(TonoPen XL; Mentor, Norwell, MA) was used to assess IOP in con-
scious, unsedated rats as previously described.39 All IOP determina-
tions were assessed by operators who were masked with respect to the
treatment applied to each eye. Animals were wrapped in a small towel
and held gently, with one operator holding the animal and another
making the readings. Five IOP readings were obtained from each eye
by using firm contact with the cornea and omitting readings obtained
as the instrument was removed from the eye. Differences among
readings were less than 10% (SE). The mean of these readings was
recorded as the IOP for this eye and this day. Mean values from each
rat were averaged, and the resultant mean value was used to compute
the group mean IOP  SE. IOP measurements were performed at the
same time each day or week (between 11:00 am and 12:00 pm) to
correct for diurnal variations in IOP.39
Electroretinography
Electroretinographic activity was assessed in dark-adapted rats as pre-
viously described.40 Briefly, after 6 hours of dark adaptation, rats were
anesthetized with intraperitoneal injection of ketamine hydrochloride
and xylazine hydrochloride under dim red illumination. Phenylephrine
hydrochloride (2.5%) and 1% tropicamide (Alcon Laboratories, Buenos
Aires, Argentina) were used to dilate the pupils, and the cornea was
intermittently irrigated with balanced salt solution (Alcon Laboratories)
to maintain the baseline recording and to prevent exposure keratopa-
thy. Rats were placed facing the stimulus at a distance of 20 cm. All
recordings were completed within 20 minutes of the induction of
anesthesia, and animals were kept warm during and after the proce-
dure. A reference electrode was placed through the ear, a grounding
electrode was attached to the tail, and a gold electrode was placed in
contact with the central cornea. A 15-W red light was used to enable
accurate electrode placement. This maneuver did not significantly
affect dark adaptation and was switched off during the electrophysio-
logical recordings. Electroretinograms (ERGs) were recorded from
both eyes simultaneously, and 10 responses to flashes of unattenuated
white light (5 ms, 0.2 Hz) from a photic stimulator (light-emitting
diodes) set at maximum brightness (9 cd  s/m2 without a filter) were
amplified, filtered (1.5-Hz low-pass filter, 1000 high-pass filter, notch
activated) and averaged (BIO-PC; Akonic, Buenos Aires, Argentina).
The a-wave was measured as the difference in amplitude between the
recording at onset and the trough of the negative deflection, and the
b-wave amplitude was measured from the trough of the a-wave to
the peak of the b-wave. Electrophysiological responses were averaged
for each run. Runs were repeated three times at 5-minute intervals to
confirm consistency, and the mean of these three runs was used for
subsequent analysis. Mean peak latencies and peak-to-peak amplitudes
of the responses from each group of rats were compared.
Flash Visual-Evoked Potentials
For recording of scotopic flash visual-evoked potentials (VEPs), two
stainless steel electrodes were surgically placed 4 mm lateral to the
interhemispheric fissure and 5.6 mm behind the bregma (active elec-
trode). Reference electrodes were placed 2 mm lateral to the midline
and 2 mm before the bregma. A ground electrode was placed in the
animal tail. Both electrodes were isolated and fixed with dental acrylic,
and the skin was sutured with nylon 5–0. Five days after electrode
implantation, VEPs were assessed as follows: after 6 hours of dark
adaptation, rats were anesthetized, pupils were dilated, and the cornea
was intermittently irrigated as previously described, under dim red
illumination. All recordings were completed within 20 minutes of the
induction of anesthesia, and animals were kept warm during and after
the procedure. Each eye was registered individually, with the contralat-
eral eye occluded, and a 70 stimuli average was registered. Eyes were
stimulated with unattenuated white light (1 Hz) from a photic stimu-
lator (light-emitting diodes) set at maximum brightness, amplified,
filtered (0.5-Hz low-pass filter, 100 high-pass filter, notch activated),
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and averaged (BIO-PC; Akonic). Amplitude between the N2 deflection
and the P2 peak was assessed, and N2 latency was measured from
onset to the second negative peak.
Light Microscopy
Eyes were enucleated after overdose of anesthetic and were immersed
immediately in a fixative containing 4% paraformaldehyde and 1%
glutaraldehyde in 0.1 M phosphate buffer (pH 7.2) for 1 hour The
nictitans membrane was maintained in each eye to facilitate orienta-
tion. The cornea and the lens were carefully removed, and the poste-
rior portions were fixed for an additional 12-hour period in the same
fixative. A cross-section of the optic nerve from control and CS-treated
eyes was removed 1.5 mm posterior to the globe and postfixed in 1%
osmium tetroxide in phosphate buffer. Nerves were processed into
epoxy resin, sectioned at 1 m, and stained with 1% toluidine blue.
Eyecups were dehydrated in an alcohol series and embedded in par-
affin. Sections (4-m thick) were cut along the horizontal meridian
through the optic nerve head and stained with hematoxylin and eosin.
Image Analysis
Microscopic images were digitally captured with a microscope (Eclipse
E400; Nikon, Tokyo, Japan [illumination: 6-V halogen lamp, 20 W,
equipped with a stabilized light source]) and a camera (SSC-DC50;
Sony, Tokyo, Japan). The microscope was set up properly for Koehler
illumination. The camera output was digitized into a 520  390 pixel
matrix (each pixel with 0–255 gray levels) with a video capture card
(WinView 601; Leadtek Research Inc., Taipei, Taiwan), displayed on a
computer monitor, and saved as an image of 24-bit RGB in .bmp
format. The digitized images were transferred to a Scion Image for
Windows analysis system (Beta 4.0.2; Scion Corporation, Frederick, MD).
Retinal morphometry was evaluated as described by Takahata et
al.,41 with minor modifications. Three sections were randomly selected
from each eye. Nine microscopic images at 1 mm from the temporal
edge of the optic disc were digitally analyzed. The light microscope
was adjusted to level 4, and a 40 CF E achromat objective was used.
At the magnification used, each pixel of the image corresponded to
0.31 m, and each field in the monitor represented a tissue area of
19318.7 m2. The thickness (in m) of the inner plexiform layer (IPL),
inner nuclear layer (INL), outer nuclear layer (ONL), and total retina
was measured. The number of cells in the ganglion cell layer (GCL) was
expressed as cells per 100 m. For each eye, results obtained from
three separate sections were averaged. and the mean of five eyes was
recorded as the representative value for each group. No attempt was
made to distinguish cell types in the GCL for enumeration of cell
number. Morphometric analysis was performed by observers masked
to the protocol used in each eye.
Optic Nerve Morphometry
Optic nerve axon counting was evaluated as described by Levkovitch-
Verbin et al.42 with minor modifications. To measure the density and
fiber diameter distributions, images were captured with a 100 ach-
romat objective from five spaced nerve regions. At the magnification
used, each pixel of the image corresponded to 3.2 m, and each field
in the monitor represented a tissue area of 4095 m2. These captured
images were edited to eliminate nonaxonal images, and the size of each
axon with its myelin sheath (diameter) and the density of axons per
square millimeter were calculated for each image. The axon number/
field in the CS-treated groups was compared with that the control
fellow eye. The number of axons counted in five images from each
nerve was approximately 10% of the total optic nerve area. The
counting process was performed by observers masked to the protocol
used in each nerve.
Statistical Analysis
Statistical analysis of results was made by a Student’s t-test or by a
two-way analysis of variance (ANOVA) followed by Student’s t-test or
Dunnett’s test.
RESULTS
Figure 1 depicts IOP values from eyes injected with vehicle or
CS (2, 4, and 8 mg), assessed 24 hours after injections. A slight
but not significant increase of IOP was observed in eyes in-
jected with 2 or 4 mg CS, whereas 8 mg CS significantly
augmented this parameter. To analyze the temporal course of
CS effect on IOP, 10 rats were injected with a single injection
of 8 mg CS in one eye, and the contralateral eye was injected
with vehicle. IOP was assessed in both eyes of these animals
before the injection, (day 0) and then it was assessed daily
beginning from 24 hours after injections, as shown in Figure 2.
The injection of CS induced an almost twofold increase of IOP
over the contralateral eye that lasted for 7 days. On day 8 after
injection, IOP in the CS-injected eyes reached control values.
To study the effect of chronic administration of CS on IOP, 10
rats were injected once a week with CS (in one eye) or vehicle
(in the contralateral eye). IOP was assessed at 7-day intervals in
both eyes of each animal, before the new injection. The mean
IOP values from these animals assessed weekly are shown in
Figure 3. The IOP of CS- treated eyes reached a steady state
level that was significantly higher than that of saline-injected
eyes and lasted the duration of the study (10 weeks). Both in
the acute and in the chronic study, a high degree of group
consistency in IOP values was found in CS-injected eyes. All
eyes, without any exception, responded with an increase of
this parameter after the injection of CS.
The functional state of the retinas from eyes weekly injected
with vehicle or CS was analyzed by scotopic electroretinogra-
phy. The average amplitudes of scotopic ERG a- and b-waves of
10 rats injected with vehicle in one eye and CS in the contralat-
eral eye during 6 weeks are depicted in Figure 4A; represen-
tative scotopic ERG traces are shown in Figure 4A (lower).
These parameters were significantly reduced in eyes receiving
CS. Similar studies were performed after 10 weeks of treatment
with vehicle or CS (Fig. 4B). Further reduction of ERG a- and
b-wave amplitudes was observed in the eyes injected with CS
for 10 weeks. Treatment with CS for 6 or 10 weeks did not
affect ERG a- and b-wave latencies compared with eyes injected
with vehicle. After 3 weeks of vehicle or CS treatment, no
changes in ERG a- and b-wave amplitude were detected (data
not shown).
FIGURE 1. Effect of a single intracameral injection of CS on rat IOP.
Eyes were injected with vehicle or CS (2–8 mg) 24 hours before IOP
assessment. A significant increase of this parameter was observed in
eyes injected with 8 (but not 2 or 4) mg CS. Data are mean SEM (n
10 eyes/group). **P  0.01, by Dunnett’s test.
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To assess the function of the visual pathway, flash VEPs
were recorded after 3, 6, and 10 weeks of ocular hypertension
induced by weekly injections of CS. A significant decrease in
the VEP N2-P2 component amplitude was observed in eyes
injected with CS for 6 and 10 weeks compared with vehicle-
injected eyes, without noteworthy changes in latency, as
shown in Figure 5 (left). Representative waveforms of VEPs for
all groups are also shown in Figure 5 (right). No changes in VEP
N2-P2 component amplitude were observed after 3 weeks of
ocular hypertension induced by CS (data not shown). ERG and
VEP responses in noninjected eyes were identical with those of
vehicle-injected eyes (data not shown).
Significant changes were observed in the retina and the
optic nerve head of eyes injected with CS for 10 weeks.
Although total retinal, IPL, INL, and ONL thickness did not
change between vehicle- and CS-injected eyes (data not
shown), a significant loss of GCL cells in CS-injected eyes for 10
weeks was observed (Fig. 6). The mean number of GCL cells/
100 m  SE from the control group was 9.2  0.5, whereas
in CS-injected eyes it was 5.9  0.7 (P  0.01; n  5 retinas/
group). At 3 or 6 weeks of treatment with vehicle or CS, no
histologic alterations at the retina or the optic nerve were
observed (data not shown). The optic nerve head from eyes
treated with CS for 10 weeks exhibited an overall loss of
staining uniformity and integrity (Fig. 7). Axons in control
optic nerve were generally uniform in shape (rounded) and
showed a variable size (Fig. 7A). In contrast, in CS-treated eyes
(Fig. 7B), spacing between bundles of axons increased. Indi-
vidual axons of treated optic nerve also exhibited distention
and distortion that resulted in a departure from the circular
morphology of normal axons. To analyze the influence of axon
diameter on ocular hypertension-induced axon loss, the num-
ber of axons in each size group from 0.05 to 0.6 m was
compared in both experimental groups (Fig. 7C). Significant
loss of large- and medium-diameter axons, but not small-diam-
eter axons, was observed.
DISCUSSION
Acute injection of CS in the rat anterior chamber significantly
increased IOP compared with vehicle-injected eyes in a dose-
dependent manner. A single injection of 8 mg CS maintained
elevated levels of IOP for 7 days. Although the intraocular fate
of the injected CS is still unknown, the slow decrease of IOP
observed after a single injection suggested that it might have
left the anterior chamber by the bulk flow or might have been
degraded by a local chondroitinase activity. Given that the
CS-induced increase in IOP was transient, weekly injections of
CS were performed to maintain a sustained increase in IOP. As
shown herein, the IOP of eyes treated weekly with CS reached
a steady state level that lasted for the duration of the study (10
weeks), which was similar to that provoked by a single injec-
tion of CS and which was significantly higher than that from
vehicle-injected eyes.
CS- and HA-containing OVDs, such as viscoelastic solution
(Viscoat 3.0% HA-4.0% CS; Alcon Laboratories) have become
almost essential tools in human anterior segment surgery to
reduce tissue trauma and endothelial cell loss and to serve as a
space maintainer. However, it is well known that those agents
are responsible for causing or exacerbating a transient, but
occasionally significant, postoperative IOP elevation. Given
that viscoelastic agents containing HA but lacking CS, such as
sodium hyaluronate (Healon [1% HA], Healon 5 [2.3% HA], and
Healon GV [1.4% HA]; Abbott Medical Optics, Santa Ana, CA),
also increase IOP in humans, the hypertensive effect of vis-
coelastic solution (Viscoat 3.0% HA-4.0% CS; Alcon Laborato-
ries) could be attributed primarily to HA. The hypertensive
effect of HA injections in the eye anterior chamber was dem-
onstrated in several species, such as rabbit43 and rat.39 To our
knowledge, the effect of CS on rat IOP was not previously
examined. It has been shown that the intracameral administra-
tion of CS increases IOP in cats but not in rabbits.44 However,
though repeated injections of CS (9 mg/eye) into the cat
anterior chamber increase 4 to 7 mm Hg above that of control
eyes, an almost 100% (10 mm Hg) increase was observed in
rat eyes injected with CS (8 mg/eye) compared with vehicle-
injected eyes. Because the rat eye anterior chamber is very
shallow, the higher hypertension provoked by CS in the rat
than in the cat eye could be attributed to the fact that actual
intracameral concentrations of CS in the rat eye should be
higher than those achieved in the cat eye. In addition, a lower
ability of CS washout in rats cannot be ruled out.
In a previous report we showed that chronic injections of
HA significantly increase rat IOP.39 The efficacy of CS in in-
creasing rat IOP was similar to that obtained through HA
FIGURE 2. Tonometer measurements of IOP in eyes treated with a
single intracameral injection of saline solution or CS. Injections were
performed at day 0, and IOP was assessed in both experimental groups
every day up to day 8. Data are mean  SEM (n  10 eyes/group).
**P  0.01, by Student’s t-test compared with IOP in saline-injected
eyes at the same intervals after injection.
FIGURE 3. Effect of chronic administration of CS on rat IOP. Intracam-
eral injections of saline solution or CS were performed weekly, after
the assessment of IOP. Data are mean  SEM (n  20 eyes/group).
**P  0.01, by Student’s t-test compared with the corresponding IOP
values of saline-injected eyes.
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injections. However, to reach a similar level of ocular hyper-
tension, a higher concentration of CS (8 mg/eye) than of HA
(0.25 mg/eye) was needed. The domain of HA is concentration
dependent and forms a continuous polymer network at a
1-mg/mL concentration. In contrast, the CS domain is limited
and forms a bottle brush configuration without a polymer
network. In addition, numerous CS binds to a single HA back-
bone to form the typical proteoglycan aggregate. Therefore,
the amount of CS required to increase IOP is expected to be
much greater than that of HA, and our results confirm the
existing knowledge of the polymerization of HA and the aggre-
gation properties of CS. Besides structural differences, differ-
ences in the turnover rate of these two GAGs could account for
this observation. Despite the relatively high concentrations of
CS needed to induce a sustained ocular hypertension, no signs
of inflammation were observed in eyes chronically injected
with CS.
It has been suggested that GAGs may reduce the functional
diameter of the flow channels through the deep corneoscleral
intertrabecular spaces or may regulate flow through the juxta-
canalicular basement membrane. Thus, it seems possible that
intracamerally injected CS could act similarly to endogenous
CS (e.g., by impeding the normal outflow of aqueous humor).
It is well known that ocular hypertension plays a causal, albeit
not necessarily exclusive, role in glaucomatous visual loss. In
fact, not all experimental models of chronic ocular hyperten-
sion cause the same alterations at the retina or the optic nerve
head level. Therefore, the following experiments were per-
formed to assess functional and histologic consequences of
chronic ocular hypertension induced by CS injections.
FIGURE 4. Scotopic ERGs in rats in-
jected with vehicle or CS. (A) Ani-
mals were injected weekly with CS
in one eye and saline solution in the
contralateral eye for 6 weeks.
(B) Effect of 10-week treatment with
vehicle or CS. (A, B, top) Average
amplitudes of scotopic ERG a- and
b-waves. (A, B, bottom) Representa-
tive scotopic ERG traces. A signifi-
cant reduction in the scotopic ERG
a- and b-wave amplitude was ob-
served in eyes injected with CS for 6
and 10 weeks. No changes between
intact and vehicle-injected eyes were
observed. Data are mean SEM (n
20 eyes/group). *P  0.05, **P 
0.01 by Student’s test.
FIGURE 5. Flash VEPs in rats injected
with vehicle or CS. Animals were in-
jected weekly with CS in one eye or
saline solution in the contralateral eye
for 6 or 10 weeks. Left: average ampli-
tudes of VEP N2–P2 component ampli-
tude. Right: representative VEP traces.
A significant reduction in flash VEP
N2–P2 component was observed in
eyes injected with CS for 6 and 10
weeks. No changes between intact
and vehicle-injected eyes for 6 or 10
weeks were observed. Data are
mean  SEM (n  20 eyes/group).
*P  0.05, **P  0.01 by Dunnett’s
test.
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Several observations support that some components of the
flash ERG can be affected in experimental models of glaucoma.
The present results support this observation because chronic
injections of CS induced a significant decrease in the scotopic
ERG a- and b-wave amplitudes evident at 6 weeks of treatment.
In addition, the fact that a further decrease in these parameters
was observed after 10 weekly injections of CS suggests a
progressive retinal dysfunction associated with chronic ocular
hypertension. In agreement with these results, in the three-
vein episcleral/limbal vein occlusion model for inducing glau-
comatous pathology in the rat eye, a significant decrease in
ERG a- and b-wave amplitude was observed.45 Similar changes
in flash ERG were described in the DBA/2 mouse with angle-
closure glaucoma46 and in eyes chronically injected with HA in
the anterior chamber.40 Furthermore, Viswanathan et al.47
showed changes in the uniform field ERG that correlate with
pattern ERG responses produced by a laser-induced glaucoma
in monkeys, and a significant reduction of scotopic ERG b-
wave amplitude was described in Brown Norway rats with
hypertonic saline injection into an episcleral vein.48
Although VEPs reflect the activity of all cells in the
pathway from photoreceptors to visual cortex, including
RGCs and their axons, few studies have previously assessed
VEPs in rodent experimental models of glaucoma. Glaucoma
FIGURE 6. Light micrographs of trans-
verse sections of a retina from a rat, in
which one eye was injected with sa-
line solution (A) and the contralateral
eye was injected with CS for 10
weeks (B). Note the diminution of
the GCL in the eye injected with CS.
Theother retinal layers showed anormal
appearance. Hematoxylin and eosin
stain.
FIGURE 7. Images of optic nerve
cross-sections in (A) control eye and
(B) CS-treated eye. (A) Healthy, in-
tact optic nerve. Note the homoge-
neity of the staining. In vehicle-in-
jected eyes, individual axons were
generally uniform in shape (arrow-
head), generally rounded, and packed
together tightly to form the fibers of
the healthy nerve. In the nerve of the
treated eye (B), a less stained area
(arrowhead) indicates a nerve alter-
ation. Disease in individual axons
was characterized by axonal disten-
tion and distortion that resulted in a
departure from the circular morphol-
ogy of normal axons (arrowheads).
There is a predominance of small-
diameter axons. Toluidine blue stain.
(C) Axonal diameter distribution in
eyes injected with vehicle or CS for
10 weeks. A significant decrease in
the number of middle and large, but
not small, axons was observed in CS-
injected eyes. Data are mean  SEM
(n  5 eyes/group). *P  0.05, by
Student’s test.
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has been reported to affect VEPs by causing both reductions
in amplitude49 and increases in latency.50 However, only
modest delays in the VEP response of eyes with glaucoma-
tous damage were shown more recently.51 The present
results indicate a significant decrease in flash VEP N2-P2
amplitude but not latency in eyes exposed to ocular hyper-
tension induced by CS, possibly because of decreased input
to the visual cortex or to alterations at the cortical levels. In
agreement with these results, VEP amplitudes are reduced in
monkeys with experimental glaucoma.52 Although species
differences in the neural generators of these flash VEP com-
ponents may exist, they appear to be generated in the
cortex. Therefore, it is tempting to speculate that chronic
injections of CS could affect optic nerve postsynaptic, in
addition to ganglion cell and optic nerve head, responses.
The retinal dysfunction described herein seems to be de-
pendent on time of hypertension. A greater decrease in ERG
and VEPs was observed at 10 weeks than at 6 weeks of ocular
hypertension, and no changes in these parameters were ob-
served after 3 weeks of treatment with CS.
As for the retinal architecture, significant damage confined
to the GCL and optic nerve axons was observed in CS-injected
eyes after 10 weeks of treatment. In control eyes, morphology
compatible with a healthy, intact optic nerve was observed.
Individual axons were generally uniform in shape and packed
together tightly to form the fibers of the nerve. In contrast, an
overall loss of nerve integrity and an alteration of axon shape
were observed in hypertensive eyes. In addition, a significant
decrease in axon number was evident; large axons were sig-
nificantly more vulnerable than small-diameter fibers. It seems
unlikely that this result may be attributable to axon shrinkage
because no shift of axonal diameter distribution to smaller sizes
was evident in CS-injected eyes. This loss of uniformity at the
level of individual axons probably underlies the overall loss of
uniformity and nerve integrity. In agreement, a preferential loss
of large optic nerve axons was demonstrated in other models
of rat and monkey experimental glaucoma.42,53
It seems improbable that CS-induced hypertension could
provoke significant ischemia. In general, the magnitude of
hypertension needed to induce retinal ischemia is much higher
than that achieved after the injection of CS. For example, it was
shown that blood flow in the rabbit optic nerve head was not
reduced by an elevation of the IOP lower than 50 mm Hg.54
Furthermore, the increase in IOP induced by CS is similar to or
lower than that obtained in other experimental models of
glaucoma in rats.40,55–57 On the other hand, it is well known
that the consequences of retinal ischemia are more severe in
periods close to the ischemic episode. If our results were the
consequence of ischemic causes, it may be presumed that
retinal function and histology should change immediately after
the first injection. This was not the case because 6 and 10
weeks of ocular hypertension were needed to induce signifi-
cant retinal dysfunction and histologic changes, respectively.
In summary, the present results indicate that weekly injec-
tions of CS induced a moderate and sustained IOP elevation,
which, in turn, provoked significant alterations in retinal func-
tion and histology compatible with human open-angle glau-
coma alterations. Moreover, taken together with evidence
showing increased levels of CS in the human TM of glaucoma
patients, the present results support that increased levels of CS
could be a causal factor in glaucomatous neuropathy.
Based on results reported herein that showed a significant
increase in rat IOP, as well as functional and histologic alter-
ations induced by CS that reproduced the primary features of
human glaucoma together with the increase of CS in TM from
glaucoma patients, it seems likely that ECM CS could play a key
role in the IOP dysregulation characteristic of glaucoma.
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